欧康医药
(833230)
| 流通市值：2.61亿 | | | 总市值：10.44亿 |
| 流通股本：1890.79万 | | | 总股本：7563.14万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 68,240,881.12 | 242,810,197.99 | 169,781,662.69 | 112,225,810.15 |
| 营业收入 | 68,240,881.12 | 242,810,197.99 | 169,781,662.69 | 112,225,810.15 |
| 二、营业总成本 | 59,113,846.37 | 228,406,123.63 | 159,181,541.57 | 103,137,248.31 |
| 营业成本 | 53,466,163.68 | 203,354,903.12 | 141,871,598.31 | 91,877,070.26 |
| 税金及附加 | 36,051.58 | 593,524.03 | 351,285.58 | 312,385.31 |
| 销售费用 | 316,262.36 | 2,209,720.96 | 1,136,632.5 | 675,185.26 |
| 管理费用 | 2,475,394.53 | 9,946,973.79 | 5,942,544.3 | 3,680,751.51 |
| 研发费用 | 2,619,655.8 | 13,509,643.28 | 10,729,104.02 | 7,304,498.51 |
| 财务费用 | 200,318.42 | -1,208,641.55 | -849,623.14 | -712,642.54 |
| 其中:利息费用 | 102,954.33 | 436,528.18 | 545,270.05 | 406,328.5 |
| 其中:利息收入 | -85,073.27 | 1,691,647.35 | 1,494,313.9 | 1,141,309.56 |
| 加:公允价值变动收益 | 69,502.35 | 995,406.31 | 21,565.2 | -62,034.8 |
| 加:投资收益 | 348,851.74 | 928,077.42 | 1,233,923.2 | 808,348.84 |
| 汇兑收益 | 309,669.3 | 437,472.44 | 769,184.46 | 775,997.84 |
| 资产处置收益 | -110,711.94 | -54,956.79 | -52,991.17 | -25,904.41 |
| 资产减值损失(新) | - | -1,293,337.57 | -478,285.04 | -478,285.04 |
| 信用减值损失(新) | 126,445.5 | -1,350,906.13 | -188,185.09 | -355,950.09 |
| 其他收益 | 448,633.06 | 2,719,965.76 | 877,464.45 | 750,069.53 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 10,319,424.76 | 16,785,795.8 | 12,782,797.13 | 10,500,803.71 |
| 加:营业外收入 | 1,565 | 243.5 | 243.5 | 243.5 |
| 减:营业外支出 | - | 28,317.5 | 3,792 | - |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 10,320,989.76 | 16,757,721.8 | 12,779,248.63 | 10,501,047.21 |
| 减:所得税费用 | 1,759,101.29 | 278,012.7 | 119,172.01 | 255,156.4 |
| 六、净利润 | 8,561,888.47 | 16,479,709.1 | 12,660,076.62 | 10,245,890.81 |
| 持续经营净利润 | 8,561,888.47 | 16,479,709.1 | 12,660,076.62 | 10,245,890.81 |
| 归属于母公司股东的净利润 | 8,654,939.61 | 16,670,309.28 | 12,660,076.62 | 10,245,890.81 |
| 少数股东损益 | -93,051.14 | -190,600.18 | - | - |
| (一)基本每股收益 | 0.11 | 0.22 | 0.17 | 0.14 |
| (二)稀释每股收益 | 0.11 | 0.22 | 0.17 | 0.14 |
| 八、其他综合收益 | - | -23,834.47 | - | - |
| 归属于母公司股东的其他综合收益 | - | -19,067.58 | - | - |
| 九、综合收益总额 | 8,561,888.47 | 16,455,874.63 | 12,660,076.62 | 10,245,890.81 |
| 归属于母公司股东的综合收益总额 | 8,654,939.61 | 16,651,241.7 | 12,660,076.62 | 10,245,890.81 |
| 归属于少数股东的综合收益总额 | -93,051.14 | -195,367.07 | - | - |
| 公告日期 | 2024-04-26 | 2024-04-17 | 2023-10-30 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |